Sign in
Not yet taking people in United StatesPhase 2/3

Dronabinol taken before sleep for people with obstructive sleep apnea using CPAP

Tests dronabinol at bedtime alongside CPAP in adults with obstructive sleep apnea.

Key facts

Who runs it
Mayo Clinic
Where
Rochester, United StatesSee the site
Trial code
Registry title
A Study Of Synthetic THC And Sleep
Status
Not yet recruiting
Phase
Phase 2/3
People taking part
72 people, planned
Started
Nov 2026
Expected to end
Apr 2028
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Dronabinol
  • Placebo
Record updated
18 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with obstructive sleep apnea who use or are starting CPAP. It tests whether dronabinol taken before sleep helps CPAP use, sleep and blood pressure.

Age
21 to 70 years
Sex
Biological males and females can join.
Disease stage
Current or new obstructive sleep apnea, with an AHI (breathing pauses per hour) between 15 - 50 events/hour.
Earlier treatment
Must be on CPAP already or have started it within 1 month. Cannot join after adult upper airway surgery for snoring or OSA, or other noninvasive OSA treatment within 1 month.
Biomarker or test result
AHI between 15 - 50 events/hour. A positive urine drug screen means you cannot join.

Main reasons for not taking part

  • BMI > 35 kg/m2
  • Diagnosed psychiatric disorders, seizures, low blood pressure, or substance or recreational drug use
  • Uncontrolled disease of the heart, lungs, liver, kidneys or other organs, including Type I Diabetes
  • Pregnant or breastfeeding
  • Taking CYP2C9 and/or CYP3A4 inhibitors or certain other drugs; bariatric surgery within 2 years; shift work within 1 month

The registry criteria, word for word

Show all 21 criteriaShow less

Who can take part

  • 21 - 70 years of age
  • Biological male or female
  • AHI between 15 - 50 events/hour
  • Current or new OSA diagnosis
  • Established or new (within 1 month) CPAP therapy

Who cannot take part

  • Use of certain antimicrobial, chemotherapeutic, anticoagulant, hypoglycemic, anti-inflammatory, psychotropic, and antihistamine drugs
  • Prescribed CYP2C9 and/or CYP3A4 inhibitors
  • Prior upper airway surgery for snoring or OSA as an adult
  • Bariatric surgery within 2 years
  • Diagnosed psychiatric disorders
  • History of seizures
  • History of substance abuse or recreational drug use or positive urine drug screen
  • History of uncontrolled disease including:; Cardiovascular; Pulmonary; Gastrointestinal; Pancreatic; Hepatic; Renal; Hematological; Endocrine (including Type I Diabetes); Neurological; Urological
  • History of shift work or rotating shifts within 1 month
  • BMI > 35 kg/m2
  • Hypotension
  • Pregnant or breastfeeding
  • Severe OSA that in the investigator's judgment should only begin CPAP treatment
  • Significant defect in nasal patency due to anatomical abnormality or uncontrolled rhinitis
  • Medically managed weight-loss program within 6 months
  • Noninvasive treatment for OSA within 1 month (self-report)

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 21 and 70 years old?

Where in United States

  • Mayo Clinic in RochesterRochester, United StatesContact: Nick WozniakNot yet recruiting

About the trial

What the trial wants to find out

The purpose of this study is to determine if oral dronabinol prior to sleep can improve CPAP adherence and sleep quality in humans. We also seek to determine if combination therapy of CPAP and pre-sleep dronabinol is associated with improved BP regulation. We will also explore BP regulatory mechanisms and whether these are impacted differently between traditional CPAP therapy and combination CPAP/dronabinol.

The 2 groups in the trial

  • DronabinolTreatment being tested

    Patients assigned to the Dronabinol arm will be taking the Study drug (Dronabinol) one hour prior to bed each night for 6 weeks.

  • PlaceboPlacebo, for comparison

    Patients assigned to the placebo arm will be taking the placebo pill (sugar pill) one hour prior to bed each night for 6 weeks.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Effects Of Nocturnal Dronabinol Use On Obstructive Sleep Apnea Treatment And Physiological Outcomes
Plain-language title
Dronabinol taken before sleep for people with obstructive sleep apnea using CPAPGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT07570953, who can take part
Record updated
18 September 2026